Pacira Biosciences Inc logo

PCRX - Pacira Biosciences Inc Share Price

$69.2 2.0  2.9%

Last Trade - 05/03/21

Mid Cap
Market Cap £2.19bn
Enterprise Value £2.15bn
Revenue £310.4m
Position in Universe 1806th / 6651
Unlock PCRX Revenue
Relative Strength (%)
1m -0.52%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -13.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
249 276.4 286.6 337.3 421 429.6 535.8 621.5 +11.5%
+872.1 +2,724 -4.51 +22.9
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, PaciraBiosciences Inc revenues increased 2% to $429.6M. Netincome totaled $145.5M vs. loss of $11M. Revenues reflectRoyalty revenue increase of 44% to $3M. Net Income reflectsAcquisition-related charges and decrease of 80% to $5.2M(expense), Research and development - Balancing valdecrease of 19% to $54.2M (expense), Other, net increasefrom $5M (expense) to $2.9M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


PCRX Revenue Unlock PCRX Revenue

Net Income

PCRX Net Income Unlock PCRX Revenue

Normalised EPS

PCRX Normalised EPS Unlock PCRX Revenue

PE Ratio Range

PCRX PE Ratio Range Unlock PCRX Revenue

Dividend Yield Range

PCRX Dividend Yield Range Unlock PCRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PCRX EPS Forecasts Unlock PCRX Revenue
Profile Summary

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 22, 2006
Public Since February 3, 2011
No. of Shareholders: 12
No. of Employees: 624
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 43,863,467
Free Float (0.0%)
Eligible for
PCRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for PCRX
Upcoming Events for PCRX
Wednesday 5th May, 2021 Estimate
Q1 2021 Pacira Biosciences Inc Earnings Release
Frequently Asked Questions for Pacira Biosciences Inc
What is the Pacira Biosciences Inc share price?

As of 05/03/21, shares in Pacira Biosciences Inc are trading at $69.2, giving the company a market capitalisation of £2.19bn. This share price information is delayed by 15 minutes.

How has the Pacira Biosciences Inc share price performed this year?

Shares in Pacira Biosciences Inc are currently trading at $69.2 and the price has moved by 67.51% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pacira Biosciences Inc price has moved by 32.13% over the past year.

What are the analyst and broker recommendations for Pacira Biosciences Inc?

Of the analysts with advisory recommendations for Pacira Biosciences Inc, there are there are currently 2 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pacira Biosciences Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Pacira Biosciences Inc next release its financial results?

Pacira Biosciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Pacira Biosciences Inc dividend yield?

Pacira Biosciences Inc does not currently pay a dividend.

Does Pacira Biosciences Inc pay a dividend?

Pacira Biosciences Inc does not currently pay a dividend.

When does Pacira Biosciences Inc next pay dividends?

Pacira Biosciences Inc does not currently pay a dividend.

How do I buy Pacira Biosciences Inc shares?

To buy shares in Pacira Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Pacira Biosciences Inc?

Shares in Pacira Biosciences Inc are currently trading at $69.2, giving the company a market capitalisation of £2.19bn.

Where are Pacira Biosciences Inc shares listed? Where are Pacira Biosciences Inc shares listed?

Here are the trading details for Pacira Biosciences Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: PCRX
What kind of share is Pacira Biosciences Inc?

Based on an overall assessment of its quality, value and momentum, Pacira Biosciences Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Pacira Biosciences Inc share price forecast 2021?

Shares in Pacira Biosciences Inc are currently priced at $69.2. At that level they are trading at 6.82% discount to the analyst consensus target price of 0.00.

Analysts covering Pacira Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of 3.497 for the next financial year.

How can I tell whether the Pacira Biosciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacira Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been 1.11%. At the current price of $69.2, shares in Pacira Biosciences Inc are trading at 16.56% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Pacira Biosciences Inc PE Ratio?

The Pacira Biosciences Inc PE ratio based on its reported earnings over the past 12 months is 18.9. The shares are currently trading at $69.2.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Pacira Biosciences Inc?

Pacira Biosciences Inc's management team is headed by:

David Stack - CHM
Laura Brege - IND
Paul Hastings - LED
Yvonne Greenstreet - IND
Kristen Williams - CAD
Charles Reinhart - CFO
Mark Froimson - IND
Dennis McLoughlin - OTH
Roy Winston - OTH
Charles Laranjeira - OTH
Max Reinhardt - PRE
Christopher Christie - DRC
Who are the major shareholders of Pacira Biosciences Inc?

Here are the top five shareholders of Pacira Biosciences Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 14.96% (6.56m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.96% (4.37m shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 6.63% (2.91m shares)
Delaware Smid Cap Growth Fund Mutual Fund
Percentage owned: 6.58% (2.88m shares)
Macquarie Investment Management Investment Advisor
Percentage owned: 6.28% (2.75m shares)
Similar to PCRX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.